Science platform

Reversal, not clearance

SenoReverse™ releases senescent cells from proliferative arrest and restores their function. The tissue retains its cells and regains its regenerative capacity.

≈ +17%
S-phase re-entry

Senescent human cells, single-cell transcriptomics.

+15.4%
Median lifespan

Aged mice, dosing from month 20 to natural death.

6 / 6
Efficacy domains favoring treatment

Aged non-human primates, seven-week interim analysis.

One axis: the cell cycle itself

Mechanism — 01

Cellular senescence is a permanent exit from the cell cycle. Once considered terminal, this arrest is now understood to be actively maintained by a network of senescence- and cell-cycle-related targets that hold the cell out of division. As arrested cells accumulate with age, tissues lose their regenerative reserve, and the arrested cells themselves become a source of chronic inflammatory signaling.

SenoReverse™ is a proprietary miRNA platform that represses this target network. A single miRNA coordinates the repression of multiple checkpoints simultaneously, as a native miRNA does, rather than cleaving a single transcript. Released from arrest, senescent cells re-enter the cell cycle and resume function.

A second, epigenetic arm of the mechanism has been characterized in neuronal models, operating in parallel with the cell-cycle arm and extending the same principle to cells of the central nervous system.

01

Repress

Represses senescence- and cell-cycle-related targets.

02

Re-enter

Senescent cells exit proliferative arrest and re-enter the cell cycle.

03

Restore

Tissue regenerative capacity is restored, and SASP signaling declines.

01 02 03 Senescent cell SenoReverse™ Cell cycle re-entry Repress → Re-enter → Restore
FIG. 01 — Mechanism SCHEMATIC

Three strategies for the senescent cell.
Only one retains it.

Why reversal — 02

The field has converged on three strategies for senescent cells. The first two change whether the cell survives or what it secretes; the third changes the state it is in.

Route 01

Clear

Senolytic

Eliminate senescent cells

Every cell removed reduces the tissue's total cell population. Because senescent cells become more prevalent with age, broad clearance carries a risk of tissue damage and weakened immune surveillance. The leading company pursuing the clearance route has since been liquidated.

Route 02

Suppress

Senomorphic

Mute their secretory signaling

The cells remain arrested, and only their secretory output is suppressed, for as long as dosing continues. The underlying proliferative arrest is unaddressed.

Route 03

Reverse

SenoReverse™

Release the proliferative arrest

The cells exit arrest, re-enter the cell cycle, and resume function; the tissue retains its cells and regains its regenerative capacity.

A fourth strategy, partial reprogramming, resets cellular age by rewriting gene expression. Its first human trial, cleared in 2026, delivers transcription factors locally to a single tissue; systemic delivery, dose control, and tumor risk remain unresolved. Reversal makes a smaller demand of the cell: it does not erase cell identity, rewrite the genome, or remove tissue, but releases the arrest so that the cell resumes its function.

The quadrant is unoccupied not because the mechanism has been disproved, but because the strategy was only formally named in the peer-reviewed literature in 2025.

Five structural advantages of reversal
01

The Tissue Keeps Its Cells

Clearance removes cells; reversal restores them. Cell number is preserved, and tissue architecture is not depleted.

02

Function Is Restored, Not Masked

The cells re-enter the cycle and resume the functions that senescence had suspended.

03

Multi-Target by Design

A single miRNA coordinates a network of checkpoints. A single-target mechanism gives the disease one point of escape; a coordinated network does not.

04

No Genomic Rewriting

The mechanism introduces no exogenous transcription factors and induces no dedifferentiation, and therefore carries none of the risk profile associated with reprogramming.

05

One Chemistry, Multiple Tissues

Readouts in skin, muscle, liver, and brain all derive from the same mechanism and the same chemistry.

Senescent cells re-enter the cell cycle

Cellular evidence — 03

In senescent human cells examined at single-cell resolution, treatment shifted the cell-cycle distribution toward proliferation. The proportion of cells in S phase rose by approximately 17%, the senescent fraction contracted, and the rejuvenated fraction, comprising cells that express proliferation markers, expanded.

The senescence program itself receded: β-galactosidase activity, the senescence marker p16, and SASP cytokine transcripts all declined, while Ki67-positive cells and proliferative capacity in population-doubling assays recovered.

The same remodeling was confirmed in living tissue. Single-cell transcriptomics of liver and skin from aged mice showed the cell-cycle composition of both organs shifting away from arrest following treatment, with senescence markers declining and proliferation markers recovering.

G1 S G2 M Control Treated S PHASE ≈ +17% Cell-cycle distribution by single-cell transcriptomics
FIG. 02 — Cell-cycle distributionSCHEMATIC
Senescence-associated β-galactosidase activityDecreased ↓
Senescence markers p21 and p16Decreased ↓
SASP cytokine transcripts (IL-6 and related)Decreased ↓
Ki67-positive cellsIncreased ↑
Proliferative capacity (population doubling)Restored
FIG. 03 — Marker panelMeasured directions

Function restored above baseline, and lifespan extended

In mice — 04

In aged mice, treatment preserved and restored physical function across endurance, strength, and body weight, the three measures that decline together in old age, and extended lifespan in a cohort followed to natural death. Treated animals rose above their own pre-dose baseline in endurance and grip strength and held body weight steady, while controls declined on all three measures over the same period.

FIG. 04

Lifespan

20 mo 30 mo 45 mo Survival (%) 0 100 50% 892 d 1,029 d Control Treated

Median lifespan 892 → 1,029 days (+15.4%); mortality hazard ratio 0.38 (95% CI 0.27–0.53); maximum lifespan +12.13%.

Aged mice to natural deathSCHEMATIC CURVE
FIG. 05

Rotarod Endurance

25 mo 27.5 30 mo Falling latency +32% Control Treated

Rotarod endurance at month 30 versus own baseline: +32%. Accelerating rotarod, 8 to 80 rpm; tested monthly from month 25.

N = 10 per groupSCHEMATIC CURVE
FIG. 06

Grip Strength

25 mo 27.5 30 mo Normalized force +11% Control Treated

Grip strength at month 30 versus own baseline: +11%; limb strength normalized to body weight.

N = 10 per groupSCHEMATIC CURVE
FIG. 07

Body Weight

20 mo 32 mo 44 mo Weight (g) Diverge from month 27 Control Treated

Body weight remained above controls from month 27 onward; n = 80 per group, weighed weekly until natural death.

20 months to natural deathSCHEMATIC CURVE

One regimen, six efficacy domains

In non-human primates — 05

In aged cynomolgus macaques with spontaneous type 2 diabetes, animals broadly comparable to humans over seventy-five, a single regimen was administered by two routes, intravenous and intrathecal. Dosing is ongoing.

Six efficacy domains were assessed: glucose control, liver function, muscle mass, neuromuscular activity, lipid metabolism, and cognition. In every one of them the between-group difference favored treatment, and in four of the six the control group moved in the opposite direction. Twelve of thirteen measured readouts moved favorably.

Glycated hemoglobin, the standard measure of long-term glycemic control, declined in treated animals to below the level targeted by standard of care. The principal target organ was unaffected: nucleic-acid drugs accumulate predominantly in the liver, yet liver enzymes declined in treated animals and rose in controls, moving monotonically at every time point in both groups. Creatinine, low at baseline in these aged animals, returned toward the reference range, accompanied by an increase in spontaneous activity. On a working-memory task, every treated animal evaluated performed below chance at baseline and above chance following treatment.

The single readout that moved in the unfavorable direction, uric acid, follows the purine pathway by which nucleic acids are metabolized, and remains under monitoring. No treatment-related adverse events, withdrawals, or dose adjustments occurred.

A single regimen produced readouts in four organ systems corresponding to four diseases: type 2 diabetes, NASH/NAFLD, sarcopenia, and Alzheimer's disease. The readouts are independent of one another, and all trace to the same upstream mechanism.

Domain 01

Glucose control

Glycated hemoglobin, pre-prandial glucose, fasting glucose and insulin.

Favorable
Domain 02

Liver function

Transaminases declined in treated animals and rose in controls.

Favorable
Domain 03

Muscle mass

Creatinine returned from below range toward the reference interval.

Favorable
Domain 04

Neuromuscular activity

Spontaneous activity increased in treated animals.

Favorable
Domain 05

Lipid metabolism

Triglycerides and total cholesterol trended favorably versus controls.

Favorable
Domain 06

Cognition

Working-memory performance moved from below chance to above chance.

Favorable
Safety

Safety & tolerability

Six electrolytes were unremarkable, and no adverse events, withdrawals, or dose adjustments occurred.

Monitored
Counter-readout

Uric acid

Follows the purine pathway of nucleic-acid metabolism; under continued monitoring.

Counter · Monitored

Built to become a medicine

Chemistry & translation — 06

The platform's chemistry is engineered for durability and tissue exposure: chemically modified, cholesterol-conjugated nucleic acids, every modification already validated in approved nucleic-acid drugs, formulated as a two-part lyophilized product that is stable through ambient distribution. Pharmacodynamic, pharmacokinetic, and toxicology studies in rats are complete, together with complement-activation safety assays, and studies in non-human primates are ongoing.

First-generation chemistry achieved human efficacy at single-digit RISC-loading efficiency. Next-generation candidates are engineered for substantially higher potency, so the platform's potency margin remains largely unexploited.